Novo Holdings to Acquire Denmark Based Ellab from EQT

Novo Holdings A/S, a leading global life sciences investor, announced that it has agreed to acquire Ellab from EQT. Headquartered in Hillerød, Denmark, Ellab (Ellab) provides validation and monitoring solutions and services for biotech and pharmaceutical processes. Its solutions and services measure and document parameters such as temperature, pressure and carbon dioxide, which helps clients to ensure consumer safety and regulatory compliance, while reducing time to market and the risk of product loss.

Initially established as a family-owned business in 1949 in Denmark, Ellab began its journey by developing temperature sensors for the food industry. Today, Ellab has transformed into a full-suite provider of validation and monitoring solutions and services for the biotech and pharmaceutical industries, serving a blue-chip customer base globally.

Novo Holdings will support the continued growth of Ellab, building on the impressive long-standing track-record, by utilising its industry network and global presence to accelerate future business expansion. Henrik Kjær Hansen, senior partner, principal investments at Novo Holdings, said: “Ellab is a company Novo Holdings has followed closely for several years. Ellab has a high quality offering for the pharma and biotech sector and aligns perfectly with our investment focus and expertise. We are very impressed by Ellab’s management team, track-record, innovation capabilities and strong customer focus, and see an excellent match between our two organisations. We look forward to partnering with the management team and employees to drive our joint strategy of growth and innovation.” Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives.

The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. Headquartered in Hillerød, Denmark, Ellab provides Validation- and monitoring solutions and services used for measuring and documenting critical parameters such as temperature, pressure and carbon dioxide in mainly biotech and pharma processes. EQT is a purpose-driven global investment organization with EUR 119 billion in assets under management within two business segments Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.